Migraine – Unmet Need – Detailed, Expanded Analysis Acute Migraine
A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings in efficacy and adverse events that create opportunities for new and improved acute migraine drugs—three of which entered the U.S. market in H1 2020. These agents became the first migraine-specific acute therapies to be approved in nearly two decades. This report provides quantitative insight into neurologists’ perceptions of key treatment drivers and goals in the acute management of migraine and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging compounds may capitalize on these opportunities.
QUESTIONS ANSWERED
What are the treatment drivers and goals in the management of acute migraine?
What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals?
What are the prevailing areas of unmet need and opportunity in the acute management of migraine?
What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for the acute treatment of migraine?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in August 2020.
Key drugs: Triptans (e.g., sumatriptan [multiple formulations]), DHE nasal spray, Reyvow, Ubrelvy, and Nurtec ODT.
Migraine - Unmet Need - Detailed, Expanded Analysis Acute Migraine
Executive Summary
Unmet Need - Acute Migraine - Executive Summary - October 2020
Introduction
Overview
Methodology
Rationale for Treatment Drivers and Goals Selection
Rationale for Drug Selection
Products for the Acute Treatment of Migraine and Rationale for Drug Selection
Treatment Drivers and Goals
Key Findings: Attribute Importance
Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Neurologists' Prescribing Decisions in Acute Migraine
Importance of Efficacy Attributes to Prescribing Decisions in Treatment of Acute Migraine: United States
Importance of Efficacy Attributes to Prescribing Decisions in Treatment of Acute Migraine: Europe
Importance of Safety and Tolerability Attributes to Prescribing Decisions in Treatment of Acute Migraine: United States
Importance of Safety and Tolerability Attributes to Prescribing Decisions in Treatment of Acute Migraine: Europe
Importance of Convenience of Administration Attributes to Prescribing Decisions in Treatment of Acute Migraine: United States
Importance of Convenience of Administration Attributes to Prescribing Decisions in Treatment of Acute Migraine: Europe
Importance of Nonclinical Factors to Prescribing Decisions in Treatment of Acute Migraine: United States
Importance of Nonclinical Factors to Prescribing Decisions in Treatment of Acute Migraine: Europe
Key Findings: Stated vs. Derived Importance
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Acute Migraine: United States
Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Acute Migraine: Europe
Product Performance Against Treatment Drivers and Goals
Key Findings
Overall Performance of Key Therapies for Acute Migraine: United States
Overall Performance of Key Therapies for Acute Migraine: Europe
Mean Overall Performance of Key Therapies for Acute Migraine: United States and Europe
Relative Performance of Key Therapies for Acute Migraine Across Select Efficacy Attributes: United States
Relative Performance of Key Therapies for Acute Migraine Across Select Efficacy Attributes: Europe
Relative Performance of Key Therapies for Acute Migraine Across Select Safety and Tolerability Attributes: United States
Relative Performance of Key Therapies for Acute Migraine Across Select Safety and Tolerability Attributes: Europe
Relative Performance of Key Therapies for Acute Migraine Across Select Convenience of Administration Attributes: United States
Relative Performance of Key Therapies for Acute Migraine Across Select Convenience of Administration Attributes: Europe
Relative Performance of Key Therapies for Acute Migraine Across Select Nonclinical Attributes: United States
Relative Performance of Key Therapies for Acute Migraine Across Select Nonclinical Attributes: Europe
Assessment of Unmet Need
Key Findings: Unmet Need in Acute Treatment of Migraine
Surveyed Neurologistsu2019 Satisfaction with the Performance of Key Therapies for Acute Migraine on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
Surveyed Neurologistsu2019 Satisfaction with the Performance of Key Therapies for Acute Migraine on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Acute Migraine: United States
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Acute Migraine: Europe
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Acute Migraine: United States
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Acute Migraine: Europe
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Acute Migraine: United States
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Acute Migraine: Europe
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Acute Migraine: United States
Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Acute Migraine: Europe
Key Findings: Unmet Need in Migraine and Related Indications
Surveyed Neurologists' Ascribed Level of Unmet Need in Migraine and Related Indications: United States
Surveyed Neurologists' Ascribed Level of Unmet Need in Migraine and Related Indications: Europe
Opportunity Analysis
Areas of Opportunity in the Acute Migraine Market and Emerging Therapy Insights
% of patients with pain relief at 2 hours (placebo-adjusted)
% of patients with pain freedom at 2 hours (placebo-adjusted)
% of patients with MBS freedom at 2 hours (placebo-adjusted)
% of patients with sustained freedom from pain at 2-24 hours (placebo-adjusted)
Safety and Tolerability Profile
Formulation
Price per dose
Conjoint Analysis-Based Simulation of a Market Scenario
Market Scenario
Acute Migraine Market Simulation: Target Product Profiles Included in the Market Scenario
Acute Migraine Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
Acute Migraine Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
Appendix
Key Abbreviations
Bibliography
Joyce Spadafora, A.L.M.
Joyce Spadafora, A.L.M., is a senior analyst on the CNS/Ophthalmology Disorders team. She authors content on various chronic pain, psychiatric, and neurological indications. Prior to joining the company, she spent several years in the biotech industry focusing on new product development and consulting. She holds a master’s degree in extension studies in psychology from Harvard University and a bachelor’s of science in mechanical engineering with biology from the Massachusetts Institute of Technology.